GLP-1 Is Reducing Consumption
and Creating New Opportunities.
With 9–10 million European adults already on appetite-suppressing medications and adoption at a fraction of US levels, the full demand reset has not yet arrived. The question is not whether it will — it is whether the industry is building for it.
The Scale That Boardrooms Are Still Underpricing
The numbers are no longer speculative. Approximately 9–10 million adults across Europe and the UK are currently taking GLP-1 receptor agonist medications — drugs originally developed for type 2 diabetes that have become the most consequential appetite-suppression tools in modern pharmacology. Each user is, on average, consuming 15–20% fewer calories per day, translating to more than 700 calories eliminated from their daily intake. That is roughly the caloric equivalent of two cheeseburgers, or three-quarters of a standard bag of crisps — simply removed from the demand equation.
Yet European adoption sits at approximately 2% of adults, against roughly 12% in the United States. The implication is straightforward: the wave is still building. ING's most transformative scenario projects that GLP-1 adoption could reduce total European calorie intake by 2.5–3.5% by 2030, with disproportionate volume pressure concentrated in the most exposed categories — snacks, confectionery, alcohol, and processed convenience foods. In the United States, where adoption is further advanced, GLP-1 households are projected to account for 35% of all food and beverage units sold by 2030, according to Circana. Where the US leads, Europe has historically followed, often within a three-to-five year lag.
This is not a diet trend. It is not a wellness cycle. The structural characterization matters: GLP-1 medications are being added to the WHO Essential Medicines List, oral formulations are entering the US market in 2026 and Europe in 2027 at substantially lower price points, and global prescription volumes for semaglutide alone surpassed 120 million active patient-months by late 2025. The mechanics of food demand are being altered at a population level, and the food industry's strategic planning cycles are, in many cases, still calibrated for a different world.
Key Takeaways
- GLP-1 adoption in Europe (≈2% of adults) remains a fraction of US levels (≈12%), meaning the main demand impact is still ahead — not behind — the industry.
- ING's transformative scenario projects a 2.5–3.5% reduction in total European calorie intake by 2030, with snacks, confectionery, and alcohol facing the steepest category exposure.
- Lindt's data upends the intuitive narrative: premium chocolate grew nearly 17% among GLP-1 users in 2025, more than double the 6.5% growth among non-users, pointing to a quality-over-quantity shift rather than category collapse.
- The innovation brief has fundamentally changed — from "more and cheaper" to "better and works harder" — with protein, fibre, satiety, and nutrient density as the new design parameters.
- For GCC food manufacturers and brands, the opportunity is early-mover: obesity prevalence in Saudi Arabia exceeds 23% and GLP-1 awareness is high, creating a platform for GLP-1-native product innovation before the category becomes crowded.
What the Data Actually Shows: Category by Category
The impact of GLP-1 adoption is not uniform across the food landscape. A 2025 study from Cornell University and Numerator found that GLP-1 users reduced spending on calorie-dense snacks by approximately 10%, with similarly steep declines across sweets, baked goods, cookies, and fast-food occasions. In the UK, 63% of GLP-1 users report actively cutting back on pizza and takeaways. Alcohol consumption is also declining meaningfully among users — a trend with significant implications not only for beverage producers but for the out-of-home dining sector, where alcohol margins frequently underwrite the broader unit economics.
But the category-level story is more complex than simple volume erosion. Lindt & Sprüngli's internal analysis — based on Circana data — found that GLP-1 households represent 17.5% of all chocolate sales despite making up only 15% of US households. Premium chocolate sales among this cohort grew by nearly 17% in 2025, compared to 6.5% among non-users. Lindt itself posted record organic growth of 12.4% for the full year, reaching revenues of CHF 5.92 billion — even after implementing price increases of roughly 19% to offset soaring cocoa costs. The premium segment absorbed both the pharmaceutical headwind and the commodity cost shock, and grew anyway.
They are upgrading to premium products. Less is more — small rewards with a moment of bliss rather than mindless munching.
Adalbert Lechner — CEO, Lindt & SprüngliThe mechanism behind Lindt's outperformance contains the strategic insight the broader industry needs to internalize. GLP-1 users are not eating less of everything indiscriminately — they are rationing their caloric budget more deliberately. When a treat survives that rationing process, it must justify its place on two dimensions simultaneously: genuine sensory satisfaction and some degree of nutritional or functional credibility. The old binary between "indulgent" and "healthy" is collapsing. The brands positioned at the intersection will capture the next growth cycle; those anchored to volume-driven, value-tier positioning in exposed categories face structural de-rating.
The Innovation Brief: Four Imperatives for Food Executives
The appropriate strategic response is not defensive reformulation. It is a rethinking of the product brief from first principles. Several imperatives emerge clearly from the demand shift already visible in US and early European data.
The GLP-1 Innovation Playbook
With daily calorie intake down 15–20%, each eating occasion must justify itself on protein content, fibre, satiety, and nutrient density. Innova Market Insights named "Powerhouse Protein" its top trend for 2026 — not protein alone, but protein plus at least one additional functional credential. The brief has shifted from "more and cheaper" to "better and works harder."
The instinct to strip products down to a lower-calorie baseline is a trap. Decades of consumer research in confectionery confirm that users penalise visible quality reduction. The correct response is to build new SKUs anchored in the GLP-1 consumer's actual needs — smaller portions with higher nutrient density, functional inclusions, and superior sensory delivery — rather than diluting the core range.
Lindt's data is not an anomaly — it is a signal. The wall between "healthy" and "indulgent" is structurally weakening. GLP-1 users show higher price inelasticity for protein products (up to 0.22 more inelastic, per Food Policy research) and higher willingness-to-pay for genuine quality. Brands that can combine authentic indulgence with demonstrable functional value — satiety, gut health support, protein delivery — own the most defensible position in the reformulated landscape.
The most durable opportunity is not retrofitting existing products — it is designing new formats from a blank sheet for a consumer whose eating patterns have been pharmacologically altered. High-protein functional beverages already represent 31.4% of the GLP-1 food and beverage market by consumption. Portion-smart indulgence, gut-health formulations addressing medication side effects, and meal components enabling self-assembled smaller occasions all represent underserved demand with first-mover advantage available today.
"-The brands that treat this as an innovation brief, not a threat, will own the next chapter."
The Oral Formulation Inflection Point
One variable that food executives cannot afford to discount is the transition of GLP-1 therapies from injectable to oral formats. Oral versions are entering the US market in 2026 and are expected in Europe by 2027. The commercial significance is substantial: oral formulations are projected to carry prices up to 50% lower than current injectables, dramatically expanding the addressable population beyond the affluent, medically-supervised cohort that has driven adoption to date.
A market currently sized at approximately $76 billion in 2025 is projected to reach $100 billion by end-2027 and potentially $162 billion by 2031. More companies are entering the space — tirzepatide (Mounjaro/Zepbound) has demonstrated efficacy superior to semaglutide in some indications — and competitive pricing pressure is building. The democratization of GLP-1 access is not a distant scenario. It is a near-term commercial reality, and the food industry's window to build infrastructure, reformulate portfolios, and establish brand positioning with this consumer cohort is narrowing.
For restaurants and foodservice operators, the calculus is equally pressing. Major chains are already trialling smaller portion formats, protein- and fibre-anchored menus, and GLP-1-compatible meal architecture. Nestlé's Vital Pursuit range — a portion-controlled, nutrient-dense frozen food line spanning pizzas to wholegrain bowls — launched in 2024 specifically targeting GLP-1 users in the US. SKU proliferation in high-protein beverages, portion-controlled snacks, and meal replacement formats has increased by an estimated 47% year-over-year since 2024, according to market data. The race is already running.
The MENA Opportunity: Early-Mover Conditions Are in Place
For food and beverage brands operating across Saudi Arabia and the wider GCC, the GLP-1 transition carries particular strategic relevance — and a more compressed timeline than the European outlook might suggest. The Kingdom's obesity profile is severe: as of 2024, 42.6% of adults aged 15 and over are classified as overweight and 23.1% as obese, with prevalence projected to reach 57% by 2035 absent meaningful intervention. Saudi Arabia's healthcare system is actively incentivising pharmaceutical weight management, and GLP-1 awareness in the Kingdom is already high — driven by social media, healthcare provider recommendations, and cross-border health tourism.
A 2026 study from King Faisal University found that 72.6% of Saudi survey participants had already heard of GLP-1 receptor agonists, with usage primarily driven by weight reduction goals. Tirzepatide (Mounjaro) was the most recognised product. Critically, current use in Saudi Arabia — while not yet at US levels — is accelerating from a base that is meaningfully higher than in most European markets, given the Kingdom's high obesity burden and relatively accessible private healthcare infrastructure.
The GCC food market therefore faces the GLP-1 transition from a position where consumer awareness is high but GLP-1-native product innovation remains almost entirely absent. Regional foodservice chains are beginning to introduce compatible menu items in 2025–2026, but the branded packaged food category in Saudi Arabia has yet to produce a dedicated GLP-1 product line. This is precisely the kind of first-mover gap that fast-moving brands — domestic and international — should be moving to close.
"The Middle East and Africa region is gaining momentum in GLP-1 adoption, particularly in GCC countries where obesity prevalence exceeds 40% and healthcare systems are actively incentivising pharmaceutical weight management."
Editorial View
The GLP-1 transition is a stress test for food companies' innovation capabilities — and a genuine sorting mechanism. Volume strategies built on habitual snacking, caloric convenience, and price-driven trade-up are the most exposed. Strategies built on genuine quality, functional delivery, and consumer trust are the most resilient.
The Lindt data point deserves to be read carefully. It is not evidence that GLP-1 is benign for the food industry. It is evidence that the industry's most premium, purpose-built brands retain pricing power and consumer loyalty precisely because they were never relying on habitual volume in the first place. The lesson is not "indulgence is safe." The lesson is that excellence is safe — and that the middle tier, built on the implicit promise of "good enough in large quantities," is the territory most at risk.
For Saudi Arabia and the Gulf, the strategic window is real and time-limited. The conditions for early-mover advantage — high obesity prevalence, rising GLP-1 awareness, under-served product innovation landscape, and Vision 2030's active push toward domestic food manufacturing capability — are converging simultaneously. The brands and manufacturers that move now, from a genuine innovation brief rather than a defensive posture, are best placed to define the next chapter of regional food and beverage.
